Affimed N.V. (0HL9.L)
USD 0.98
(-10.93%)
USD 0.98
(-10.93%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 463 Thousand EUR | -26.27% |
| 2022 | 628 Thousand EUR | 49.17% |
| 2021 | 421 Thousand EUR | 71.14% |
| 2020 | 246 Thousand EUR | -16.89% |
| 2019 | 296 Thousand EUR | 13.85% |
| 2018 | 260 Thousand EUR | 7.88% |
| 2017 | 241 Thousand EUR | 22.34% |
| 2016 | 197 Thousand EUR | -13.6% |
| 2015 | 228 Thousand EUR | 14.57% |
| 2014 | 199 Thousand EUR | 42.14% |
| 2013 | 140 Thousand EUR | 15.7% |
| 2012 | 121 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | - EUR | -100.0% |
| 2024 Q1 | 700 Thousand EUR | 51.19% |
| 2023 Q3 | 809 Thousand EUR | 16.57% |
| 2023 Q4 | 463 Thousand EUR | -42.77% |
| 2023 FY | 463 Thousand EUR | -26.27% |
| 2023 Q1 | 667 Thousand EUR | 6.21% |
| 2023 Q2 | 694 Thousand EUR | 4.05% |
| 2022 FY | 628 Thousand EUR | 49.17% |
| 2022 Q1 | 485 Thousand EUR | 15.2% |
| 2022 Q3 | 673 Thousand EUR | 17.86% |
| 2022 Q4 | 628 Thousand EUR | -6.69% |
| 2022 Q2 | 571 Thousand EUR | 17.73% |
| 2021 Q1 | 435 Thousand EUR | 76.83% |
| 2021 FY | 421 Thousand EUR | 71.14% |
| 2021 Q4 | 421 Thousand EUR | -39.16% |
| 2021 Q3 | 692 Thousand EUR | 13.07% |
| 2021 Q2 | 612 Thousand EUR | 40.69% |
| 2020 Q2 | 421 Thousand EUR | 24.93% |
| 2020 FY | 246 Thousand EUR | -16.89% |
| 2020 Q1 | 337 Thousand EUR | 13.85% |
| 2020 Q4 | 246 Thousand EUR | -40.0% |
| 2020 Q3 | 410 Thousand EUR | -2.61% |
| 2019 Q3 | 330 Thousand EUR | 0.0% |
| 2019 Q2 | 330 Thousand EUR | 1.54% |
| 2019 Q1 | 325 Thousand EUR | 25.0% |
| 2019 FY | 296 Thousand EUR | 13.85% |
| 2019 Q4 | 296 Thousand EUR | -10.3% |
| 2018 Q3 | 320 Thousand EUR | 19.85% |
| 2018 Q2 | 267 Thousand EUR | 1.91% |
| 2018 Q1 | 262 Thousand EUR | 8.71% |
| 2018 FY | 260 Thousand EUR | 7.88% |
| 2018 Q4 | 260 Thousand EUR | -18.75% |
| 2017 Q3 | 282 Thousand EUR | 12.8% |
| 2017 Q4 | 241 Thousand EUR | -14.54% |
| 2017 FY | 241 Thousand EUR | 22.34% |
| 2017 Q2 | 250 Thousand EUR | 30.89% |
| 2017 Q1 | 191 Thousand EUR | -3.05% |
| 2016 FY | 197 Thousand EUR | -13.6% |
| 2016 Q3 | 253 Thousand EUR | 8.58% |
| 2016 Q2 | 233 Thousand EUR | -3.72% |
| 2016 Q1 | 242 Thousand EUR | 6.14% |
| 2016 Q4 | 197 Thousand EUR | -22.13% |
| 2015 FY | 228 Thousand EUR | 14.57% |
| 2015 Q3 | 239 Thousand EUR | 7.66% |
| 2015 Q2 | 222 Thousand EUR | 10.45% |
| 2015 Q1 | 201 Thousand EUR | 1.01% |
| 2015 Q4 | 228 Thousand EUR | -4.6% |
| 2014 Q1 | 138 Thousand EUR | -1.43% |
| 2014 Q3 | 187 Thousand EUR | 8.09% |
| 2014 Q4 | 199 Thousand EUR | 6.42% |
| 2014 Q2 | 173 Thousand EUR | 25.36% |
| 2014 FY | 199 Thousand EUR | 42.14% |
| 2013 Q4 | 140 Thousand EUR | 0.0% |
| 2013 FY | 140 Thousand EUR | 15.7% |
| 2012 FY | 121 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Editas Medicine, Inc. | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 99.131% |
| Cara Therapeutics, Inc. | 2.82 Million USD | 83.587% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.994% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 99.402% |
| Perrigo Company plc | 1.14 Billion USD | 99.959% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | 95.23% |
| Illumina, Inc. | 587 Million USD | 99.921% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.991% |
| Nektar Therapeutics | 16.1 Million USD | 97.124% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | 95.536% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 98.9% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 99.958% |
| Waters Corporation | 516.23 Million USD | 99.91% |
| Biogen Inc. | 2.52 Billion USD | 99.982% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | 95.79% |
| bluebird bio, Inc. | 22.91 Million USD | 97.98% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 99.294% |
| FibroGen, Inc. | 41.56 Million USD | 98.886% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 99.955% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 99.481% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 99.224% |
| Myriad Genetics, Inc. | 20.1 Million USD | 97.697% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 99.982% |
| OPKO Health, Inc. | 65.69 Million USD | 99.295% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 99.982% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 118.944% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 99.88% |
| Exelixis, Inc. | 17.32 Million USD | 97.327% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 99.937% |
| uniQure N.V. | 12.02 Million USD | 96.149% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | 96.941% |
| Verastem, Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | 98.371% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 99.857% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 98.791% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | 94.01% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 99.637% |
| TG Therapeutics, Inc. | 39.82 Million USD | 98.837% |
| Blueprint Medicines Corporation | 21.22 Million USD | 97.818% |
| Insmed Incorporated | 83.24 Million USD | 99.444% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | 97.573% |
| Incyte Corporation | 62.97 Million USD | 99.265% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 99.859% |